Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-502-2311
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
Employees92
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
How were Stemline Therapeutics' earnings last quarter?
Stemline Therapeutics Inc (NASDAQ:STML) posted its quarterly earnings data on Friday, August, 2nd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.05. The biopharmaceutical company had revenue of $13.01 million for the quarter, compared to analyst estimates of $8.84 million. View Stemline Therapeutics' Earnings History.
When is Stemline Therapeutics' next earnings date?
What price target have analysts set for STML?
6 brokers have issued 12 month price objectives for Stemline Therapeutics' stock. Their forecasts range from $17.00 to $35.00. On average, they expect Stemline Therapeutics' stock price to reach $25.20 in the next year. This suggests a possible upside of 183.0% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.
What is the consensus analysts' recommendation for Stemline Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.
What are Wall Street analysts saying about Stemline Therapeutics stock?
Here are some recent quotes from research analysts about Stemline Therapeutics stock:
- 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (8/7/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a discounted cash flow based asset value of $1.46B for 15% discount rate and 2% terminal growth rate. The company has approximately 42M shares outstanding after the recent financing. Probabilities of market entry ascribed to SL-401 and SL-701 are 100% and 45%, respectively." (1/25/2019)
Has Stemline Therapeutics been receiving favorable news coverage?
Press coverage about STML stock has trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Stemline Therapeutics.
Are investors shorting Stemline Therapeutics?
Stemline Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,130,000 shares, an increase of 24.6% from the August 30th total of 4,920,000 shares. Based on an average daily trading volume, of 620,300 shares, the days-to-cover ratio is currently 9.9 days. Currently, 15.2% of the shares of the stock are short sold. View Stemline Therapeutics' Current Options Chain.
Who are some of Stemline Therapeutics' key competitors?
Some companies that are related to Stemline Therapeutics include Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Radius Health (RDUS), Turning Point Therapeutics (TPTX), Zymeworks (ZYME), Innoviva (INVA) and Esperion Therapeutics (ESPR).
What other stocks do shareholders of Stemline Therapeutics own?
Who are Stemline Therapeutics' key executives?
Stemline Therapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
- Mr. Robert Francomano, Sr. VP & Global Head of Commercial
- Mr. John A. Salvagno, Sr. VP of Quality & Operations
How do I buy shares of Stemline Therapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Stemline Therapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $8.91.
How big of a company is Stemline Therapeutics?
Stemline Therapeutics has a market capitalization of $391.43 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.View Additional Information About Stemline Therapeutics.
What is Stemline Therapeutics' official website?
How can I contact Stemline Therapeutics?
Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
